mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for LGALS2
Gene summary
Basic gene Info.Gene symbolLGALS2
Gene namelectin, galactoside-binding, soluble, 2
SynonymsHL14
CytomapUCSC genome browser: 22q13.1
Type of geneprotein-coding
RefGenesNM_006498.2,
DescriptionS-Lac lectin 2beta-galactoside-binding lectin L-14-IIgal-2galectin 2galectin-2lactose-binding lectin 2
Modification date20141207
dbXrefs MIM : 150571
HGNC : HGNC
Ensembl : ENSG00000100079
HPRD : 08859
Vega : OTTHUMG00000150590
ProteinUniProt: P05162
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_LGALS2
BioGPS: 3957
PathwayNCI Pathway Interaction Database: LGALS2
KEGG: LGALS2
REACTOME: LGALS2
Pathway Commons: LGALS2
ContextiHOP: LGALS2
ligand binding site mutation search in PubMed: LGALS2
UCL Cancer Institute: LGALS2
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID


Top
Ligand binding site mutations for LGALS2

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
R49F50ILUAD1
R70,E68Q69EOV1
H45H45YSTAD1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for LGALS2
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
H45H45Y-0.96123499
R49F50I-0.83763188
E68Q69E-0.50540255
R70Q69E-0.50540255
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for LGALS2 from PDB

Top
Differential gene expression and gene-gene network for LGALS2
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of LGALS2 and the right PPI network was created from samples without mutations in the LBS of LGALS2. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for LGALS2
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0027051Myocardial Infarction14Biomarker, GeneticVariation
umls:C0520459Enterocolitis, Necrotizing1Biomarker

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for LGALS2
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ExperimentalDB02379Beta-D-GlucoseSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of LGALS2 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
GALBETA-D-GALACTOSE1hlcAH45 R49 E68
GALBETA-D-GALACTOSE1hlcBH45 R49 E68
BGCBETA-D-GLUCOSE1hlcAR49 E68 R70
BGCBETA-D-GLUCOSE1hlcBR49 E68 R70


Top
Conservation information for LBS of LGALS2
Multiple alignments for P05162 in multiple species
LBSAA sequence# speciesSpecies
E68SNWGQEQREDH1Homo sapiens
E68GRWGQEQRENH1Mus musculus
E68SSWGQEQRENH1Rattus norvegicus
H45ETLNLHFNPRF2Mus musculus, Rattus norvegicus
H45DKLNLHFNPRF1Homo sapiens
N47LNLHFNPRFSE1Homo sapiens
N47LNLHFNPRFDE1Mus musculus
N47LNLHFNPRFNE1Rattus norvegicus
N58STIVCNSLDGS1Homo sapiens
N58STIVCNTSEGG1Mus musculus
N58STIVCNTLDGS1Rattus norvegicus
R120SYLSVRGGFNM1Homo sapiens
R120HYLSM-GGLQI1Mus musculus
R120RYLSM-DGLQI1Rattus norvegicus
R49LHFNPRFSEST1Homo sapiens
R49LHFNPRFDEST1Mus musculus
R49LHFNPRFNEST1Rattus norvegicus
R70WGQEQREDHLC1Homo sapiens
R70WGQEQRENHMC1Mus musculus
R70WGQEQRENHSC1Rattus norvegicus
W65LDGSNWGQEQR1Homo sapiens
W65SEGGRWGQEQR1Mus musculus
W65LDGSSWGQEQR1Rattus norvegicus


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas